Adverse events after the use of benznidazole in infants and children with Chagas disease

Pediatrics

Volumn 127, Issue 1, 2011, Pages

  Altcheh, Jaime ^a   Moscatelli, Guillermo ^a   Moroni, Samanta ^a   Garcia Bournissen, Facundo ^b   Freilij, Hector ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adverse events; Benznidazole; Chagas disease; Children; Congenital; Infant; Pediatric pharmacology

Indexed keywords

BENZNIDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ARGENTINA; ARTICLE; BLURRED VISION; CHAGAS DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; ECZEMA; EOSINOPHILIA; ERYTHEMA; HEADACHE; HUMAN; INCIDENCE; INFANT; LEUKOPENIA; MUSCLE CRAMP; MYALGIA; NEWBORN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; URTICARIA; VOMITING;

ADOLESCENT; CHAGAS DISEASE; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; NITROIMIDAZOLES; PROSPECTIVE STUDIES; TRYPANOCIDAL AGENTS; YOUNG ADULT;

EID: 78650788684     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1172     Document Type: Article

References (43)

1. Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis. 1995;21(3):551-555
2. Gurtler RE, Segura EL, Cohen JE. Congenital transmission of Trypanosoma cruzi infection in Argentina. Emerg Infect Dis. 2003;9(1):29-32 (Pubitemid 36110199)
3. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA. 2007;298(18):2171-2181
4. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102(suppl 1):75-85
5. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet. 2003;362(9394):1469-1480
6. Teixeira AR, Nascimento RJ, Sturm NR. Evolution and pathology in Chagas disease: a review. Mem Inst Oswaldo Cruz. 2006;101(5):463-491
7. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006;19(6):583-587
8. World Health Organization Expert Committee on the Control of Chagas Disease. Control of Chagas Disease Second Report of the WHO Expert Committee. 905th ed. Geneva, Switzerland: World Health Organization; 2002
9. Organizacion Panamericana de la Salud. Estimación Cuantitativa de la Enfermedad de Chagas en las Américas. Washington, DC: Organizacion Panamericana de la Salud OPS/.HDM/CD/425-06; 2006
10. World Health Organization Expert Committee on the Control of Chagas Disease. Control of Chagas Disease Second Report of the WHO Expert Committee. Geneva, Switzerland: World Health Organization; 2002
11. Sosa ES, Segura EL. Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina [in Spanish]. Medicina (B Aires). 1999;59(suppl 2):166-170
12. Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H. Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop. 2005;38(suppl 2):41-45
13. Sosa ES, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998;59(4):526-529
14. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127(1):151-162 (Pubitemid 24040442)
15. Moya PR, Paolasso RD, Blanco S, et al. Treatment of Chagas' disease with nifurtimox during the first months of life [in Spanish]. Medicina (B Aires). 1985;45(5):553-558
16. Russomando G, Figueredo A, Almiron M, Sakamoto M, Morita K. Polymerase chain reaction-based detection of Trypanosoma cruzi DNA in serum. J Clin Microbiol. 1992;30(11):2864-2868
17. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40(1):1-10
18. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina [in Portuguese]. Rev Soc Bras Med Trop. 2004;37(5):365-375
19. Fabbro DS, Arias E, Streiger M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo. 2000;42(2):99-109
20. Streiger M, Fabbro D, del Barco M, Beltramino R, Bovero N. Congenital Chagas disease in the city of Santa Fe: diagnosis and treatment. Medicina (B Aires). 1995;55(2):125-132
21. Garcia-Bournissen F, Altcheh J, Giglio N, Mastrantonio G, la Vedova CO, Koren G. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Paediatr Drugs. 2009;11(1):33-37
22. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz. 2007;102(suppl 1):95-97
23. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7(2):157-163
24. Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm. 1999;27(6):625-644
25. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259
26. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93-102
27. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997;17(6):374-389
28. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355-365
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245 (Pubitemid 12149145)
30. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96
31. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348 (9039):1407-1413
32. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3(7):e488
33. Faria CR, Souza SEM, Rassi A. Peripheral polyneuropathy induced by benzonidazole in the treatment of Chagas; disease [in Portuguese]. Arq Neuropsiquiatr. 1986;44(2):125-129 (Pubitemid 16117640)
34. Flores-Vieira CL, Barreira AA. Experimental benznidazole encephalopathy: I. Clinicalneurological alterations. J Neurol Sci. 1997;150(1):3-11
35. Flores-Vieira CL, Chimelli L, Franca Fernandes RM, Barreira AA. Experimental benznidazole encephalopathy: II. Electroencephalographic and morphological alterations. J Neurol Sci. 1997;150(1):13-25 (Pubitemid 27303789)
36. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134-1138
37. Teixeira AR, Cordoba JC, Souto M, I, Solorzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg. 1990;43(2):146-158 (Pubitemid 20268882)
38. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev Anti Infect Ther. 2007;5(4):717-726
39. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-175
40. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118(2):250-267
41. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167
42. th Pediatric Research meeting in Catamarca, Argentina; 2009
43. Sosa ES, Segura EL. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz. 1999;94(Suppl 1):363-365